China Pharma Holdings Inc.

11/17/2026 | Press release | Distributed by Public on 11/17/2026 13:45

Late Filing Notice (Form NT 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: September 30, 2026

☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q

For the Transition Period Ended: _____________________________________

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

China Pharma Holdings, Inc.

Full Name of Registrant:

N/A

Former Name if Applicable:

Second Floor, No. 17, Jinpan Road

Address of Principal Executive Office (Street and number):

Haikou, Hainan Province, China 570216

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The compilation, dissemination and review of the information required to be presented in the quarterly report on Form 10-Q for the quarterly period ended September 30, 2026 (the "Quarterly Report") imposed time constraints that have rendered timely filing of the Quarterly Report impracticable without undue hardship and expense to the registrant. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the registrant endeavors to file its Quarterly Report no later than November 23, 2026.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Zhilin Li +86-898 6681-1730
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☒ Yes ☐ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Management estimates to have several material changes to the registrant's results of operations, which are still subject to change upon the completion of the financial statements, including: (i) revenue increased to approximately $1.15 million for the three months ended September 30, 2026 from approximately $0.76 million for the three months ended September 30, 2025; (ii) loss from operations increased to approximately $1.88 million for the three months ended September 30, 2026 from approximately $0.63 million for the three months ended September 30, 2025; (iii) net loss increased to approximately $1.90 million for the three months ended September 30, 2026 from approximately $0.65 million for the three months ended September 30, 2025; and (iv) comprehensive loss increased to approximately $1.49 million for the three months ended September 30, 2026 from approximately $0.59 million for the three months ended September 30, 2025. Additional narrative and quantitative disclosure regarding the registrant's results of operations for the three months ended September 30, 2026 will be disclosed in the registrant's Quarterly Report on Form 10-Q.

2

China Pharma Holdings, Inc.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 17, 2026 By: /s/ Zhilin Li
Name: Zhilin Li
Title: Chief Executive Officer
(Principal Executive Officer)

ATTENTION

Intentional misstatements or omissions of fact constitute Federal criminal violations. (See 18 U.S.C. 1001).

3

China Pharma Holdings Inc. published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 17, 2026 at 19:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]